Kornimate/medical-research-clean huggingface dataset:
pharyngitis,group a streptococcal infection,rapid streptococcal test,throat swab culture

Conditions: Pharyngitis

Summary: comparison of immunochromatographic test for rapid detection of group a streptococcal antigen with culture in pediatric patients.

throat swabbing by two port germ amines agar (copan) swabs,then the swabs were randomly labeled as swab a and swab b.swab a was processed for rapid streptococcal test and swab b was processed for culture in colombia blood agar.all patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.

Eligibility criteria:
inclusion criteria: * all patients presenting with the possible diagnosis of bacterial pharyngitis,between 1-14 years of age. exclusion criteria: * patients who received antibiotics within two weeks from presentation

Keywords: group a streptococcal pharyngitis rapid streptococcal test throat swab culture
concentrated growth factors in treatment of intrabony defects in localized aggressive periodontitis

Conditions: Aggressive Periodontitis

Summary: a total of 20 intra-bony defects in 10 lap patients were randomly assigned into two groups 10 defects each in a split-mouth design. group i treated by surgery plus bio-oss bone graft + collagen membrane (control group). group ii, treated by surgery plus bio-oss bone graft + cgf membrane (test group). gingival index (gi), bleeding on probing (bop), probing pocket depth and clinical attachment level (cal) were assessed at baseline, 3, 6, and 12 months. cone beam radiograph evaluation was taken at baseline, and 12 months after surgery..

full mouth scaling and root planing was done for all patients followed by augmentin i gm and metronidazole 500 mg twice daily for 7 days. additionally, comprehensive oral hygiene instructions were given to the patients. sites grouping four weeks following phase i therapy, the twenty defect sites were randomly classified by sealed envelopes into two groups ten each by a masked supervisor as follows: group i (10 sites) received surgery + bio-oss bone graft (geistlich pharma ag, wolhusen, switzerland) + collagen membrane (control group). group ii (10 sites) received surgery + bio-oss bone graft +concentrated growth factors membrane (tested group). after the administration of local anesthesia (xylocaine 2% adrenaline 1:80,000, icpa, india), buccal and lingual sulcular incisions were made, and mucoperiosteal flaps were elevated. thorough debridement of the defects was achieved with hand instruments. the surgical area was irrigated with copious amounts of sterile saline. bio-oss granules were placed into the defects and the cgfs membrane was trimmed and adapted over the entire defect to cover 2-3 mm of the surrounding alveolar bone and to ensure the stability of the wound and the graft material. for control sites, bio-oss grafts and a bioresorbable collagen membrane were trimmed and adjusted over the defect in such a way that the whole defect and 2-3 mm of the surrounding alveolar bone were completely covered. then the flap was repositioned to achieve complete interproximal closure. the flap was then sutured with 4-0 absorbable sutures with single interrupted sutures. a periodontal pack was applied over the surgical area for 10 days.

Eligibility criteria:
inclusion criteria: * presence of angular periodontal intra-bony defects with clinical attachment loss ≥5 mm measured from cej to the deepest propping depth with no evidence of gingival recession * optimal compliance as evidenced by no missed treatment appointment and high attitude towards oral hygiene exclusion criteria: * patients with relevant medical conditions that may affect periodontal regeneration and surgery * smokers, pregnant or lactating women * those whom periodontal surgery had previously been carried out on the selected site, * and patients who taking any drug known to affect the number or function of platelets

Keywords: aggressive periodontitis intrabony defect, concentrated growth factors membrane
efficacy and safety of indacaterol acetate delivered via the concept1 inhalation device in children greater or equal to 6 and less than 12 years of age with asthma

Conditions: Asthma

Summary: this study is designed to explore lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with historical data in adults, to identify an appropriate dose to phase iii evaluation.


Eligibility criteria:
inclusion criteria: * male and female children ≥ 6 years and \< 12 years with confirmed diagnosis of asthma for at least 1 year prior to study enrollment. * written informed consent by parent(s)/legal guardian(s) and depending upon their age and local requirements a consent or assent for the patient. * patients receiving daily treatment with a stable low dose inhaled corticosteroid (ics) (with or without additional controller), or patients receiving daily treatment with a stable mid-dose ics (monotherapy or together with ltra) for at least 4 weeks prior to screening, and able to tolerate fluticasone propionate 100 μg b.i.d. inhaler starting at visit 1 (or soon after). * patients with a pre-bronchodilator fev1 ≥ 50% and ≤ 90% of the predicted normal value for the patient at the start and end of run-in (visits 101 and 199). * patients who demonstrate an increase in fev1 of 12% within 30 minutes after administration of 400 μg salbutamol/360 μg albuterol (or equivalent dose) at visit 101. all patients must perform a reversibility test at visit 101. exclusion criteria: * patients taking a mid-dose ics (per gina guidelines) in combination with laba or any patient taking high-dose ics. * evidence of unstable disease within 4 weeks prior to screening (visit 1). * patients who have had an asthma attack/exacerbation requiring systemic steroids (scs) or hospitalization or emergency room visit within 3 months prior to visit 1 (screening) or more than 3 separate exacerbations in the 12 months preceding visit 1. * suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening (visit 1). * prior intubation for asthma.

Keywords: indacaterol acetate, asthma, gina 2015, pediatrics
cystic fibrosis in the kidney: monitoring the effectiveness of elexacaftor/tezacaftor/ivacaftor in urine after a short pause of therapy

Conditions: Cystic Fibrosis (CF); CFTR Gene Mutation

Summary: in cystic fibrosis (cf) renal base excretion is impaired, due to mutations in the cystic fibrosis transmembrane regulator (cftr) gene, since cftr function is crucial in regulation of the kidney's hco3- excretion. the investigators suggest that challenged urine hco3- excretion is a biomarker of cftr function, which can be used to evaluate the extent of cftr dysfunction and the possible correcting effects of cftr modulating therapy. this study aims to evaluate changes in challenged urine hco3- excretion in cf patients, who are currently in treatment with the triple cftr modulator combination therapy, elexacaftor/tezacaftor/ivacaftor (eti), before, during, and after a short treatment pause.


Eligibility criteria:
inclusion criteria: * adult (age \>17 years) cf patients. * normal kidney function estimated by egfr\>90. * adults capable of understanding and voluntarily consenting. exclusion criteria: * critical acute illness. * severe lung disease (ppfev1\<40%). * adults not capable of understanding and voluntarily consenting.
stress and ckd among african americans

Conditions: Chronic Kidney Disease

Summary: the goal of this study is to determine whether experiencing stress from discrimination may increase chronic kidney disease (ckd) progression in african americans. study participation occurs over the course of 2 days, and participant time burden is expected to be about 4.5 hours, plus a 24-hour period of wearing a blood pressure monitor.

on day 1, the project coordinator will explain the study to participants and answer any questions he/she may have. those who agree to participate in the study will provide consent at the clinic and will also be asked to complete a questionnaire on an ipad in a small, private room at the clinic. the participant will complete the questionnaire alone, however, the project coordinator will read questions aloud if the participant chooses. before leaving on day 1, participants will fitted with a blood pressure monitor to be worn for the next 24 hours. the clinical intervention portion of the study occurs during the morning of day 2 (between 9:00 am and 11:00 am). participants will be instructed to bring the blood pressure monitor and a list of current medications (or the actual medications) with them. first, participants will provide a urine sample and undergo blood pressure testing. a research nurse will insert a catheter (a small thin tube) into the participant's vein, and allow a 30-minute resting period so that the participant gets used to the catheter, and then take a baseline blood draw. participants will judge how distressed they feel in that moment using a standard scale and tell the project coordinator his/her rating. next, participants will be randomized to one of two study arms such that half will recall the racial experience and half will recall the non-racialized stressful event. an audience of two observers of same race will wear white coats and watch as the participants recall the stressful events. the research nurse will draw blood and take blood pressure measurements at multiple time points during both recall experiences. immediately before and after each recall task, the participant will again judge how distressed he/she is feeling in that moment using the same scale as before. the project coordinator will explain the purpose of the story recall and common ways that individuals may respond to the task (such as feeling anxious after the task). a total of 100 people will take part in this study.

Eligibility criteria:
inclusion criteria: * patient at emory university hospital midtown * self-identify as african american or black * estimated glomerular filtration rate (egfr) ≥ 15, or \<90 exclusion criteria: * mental disorder that prevents the completion of the computer assisted personal interview (capi) and the stressful recall manipulation * currently on maintenance dialysis * unable or unwilling to undergo intravenous catheterization

Keywords: social stress inflammation
effect of rhdl on atherosclerosis - safety and efficacy: the erase trial

Conditions: Acute Coronary Syndromes

Summary: currently available therapies to treat acute coronary syndromes(acs) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. this study will assess the effects of rhdl compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (ivus) in patients after acute coronary syndromes (acs).


Eligibility criteria:
inclusion criteria: * male or female 30 - 75 years of age * recent acute coronary syndrome, defined as unstable angina, non-q wave myocardial infarction, or st elevation indicative of myocardial infarction, within the last 14 days exclusion criteria: * \>50% stenosis by visual angiographic estimation in the left main artery * renal insufficiency * severe liver disease * congestive heart failure as defined by the nyha classification as functional class iii or class iv * previous or planned coronary artery bypass surgery
a study in people with abnormal fat levels in the blood

Conditions: Dyslipidemia

Summary: the purposes of this study are to determine: * the safety of the study medication and any side effects that might be associated with it; * whether the study medication can help patients with low levels of 'good' cholesterol (hdl-c) and high blood fats or triglycerides (tg); * how much of the study medication should be given to patients; * how the study medication compares to fenofibrate (lofibra), a drug used for people with low levels of hdl-c and high levels of tg.


Eligibility criteria:
inclusion criteria: * men and women between 18 and 80 years of age * people with abnormal fat levels in the blood (low hdl, high tg) exclusion criteria: * people with diabetes * people whose blood pressure is greater than 160/95 mm hg, on or off blood pressure medicine * people who have had frequent chest pain or unstable angina, a heart attack or a heart procedure, including stent placement, within the past 3 months
methodology issues in a tailored light treatment for persons with dementia - aim 2

Conditions: Alzheimer's Disease; Sleep Disturbance

Summary: aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with alzheimer's disease. participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.


Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease or related dementia with a montreal cognitive assessment score \<25 * sleep disturbance with a pittsburgh sleep quality index score ≥5 exclusion criteria: * extensive brain vascular disease, traumatic brain injury, multiple sclerosis, parkinson's disease * obstructing cataracts * severe macular degeneration * use of sleep medication * use of oral melatonin * untreated moderate to severe sleep apnea * severe restless leg syndrome * blindness
xience prime sv everolimus eluting coronary stent japan post marketing surveillance (xience prime sv japan pms)

Conditions: Ischemic Heart Disease; Angina Pectoris; Coronary Artery Disease; Coronary Artery Occlusion; Myocardial Ischemia

Summary: the objective of the study is to evaluate the safety and efficacy of xience prime sv in real world practice in japanese hospitals.

based on good post-marketing study practice (gpsp) regulation, general patient population with ischemic heart disease who are eligible for treatment with xience prime sv everolimus eluting stent will be registered, with no particular inclusion/exclusion criteria, and may be eligible for angiographic follow-up at eight months and clinical follow-up at one year.

Eligibility criteria:
* patient informed consent is required for registration of this pms. in cases where patient informed consent (or providing some type of information) is required for pms per the participating site policy, the sponsor will cooperate as needed. * if it is known at the time of index procedure that the patient is not able to return for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up, then the patient should not be registered in the pms. * patients who are treated (stent delivery system inserted into the body) by xience prime sv will be registered (including provisional stenting for side branch treatment but excluding bail-out only use). * the observations will be compiled on a per-patient basis even if multiple stents are implanted during the index procedure. * a patient whose side-branch is treated by xience prime sv can be registered. in such a case, main vessel should be treated by xience prime. * a patient who are treated by other drug eluting stent (des) for planned stent and xience prime sv for bail-out purpose cannot be registered. * additional revascularization procedures as a part of adverse event treatment and planned staged procedures will not be considered as another registration, or adverse events. * a patient who is treated, but failed to be implanted by xience prime sv and finally treated by other devices only (no xience prime sv are implanted) must also be registered. in such a case, only the stent information, device deficiency information and reportable adverse events related to the prime stent, if any, are required to be captured. follow-up of the patient who does not receive any xience prime sv stent is not required. * a patient may have another lesion(s) that may be treated by larger diameter stent(s). in such a case, treatment by xience prime is preferable. lesion(s) treated by other than xience prime is not considered as the target lesion.

Keywords: drug eluting stent stent real world
intraocular pressure (iop) assessed by dynamic contour tonometer (dct) and goldman applanation tonometry (gat)

Conditions: Uveitis; Intraocular Pressure

Summary: the purpose of this study is to evaluate an assessment of the intraocular pressure with the dynamic contour tonometry and the goldmann applanation tonometry in patients with active anterior uveitis.

keratoprecipitates are often found in anterior uveitis. also elevation of the iop can be seen in these patients. goldmann applanation tonometry is the standard technique to assess the iop but depends on the corneal thickness. therefore iop is measured by goldmann and dynamic contour tonometry and corneal thickness is quantified by orbscan at active uveitis and after the keratoprecipitates have disappeared.

Eligibility criteria:
inclusion criteria: * active anterior or panuveitis with keratoprecipitates exclusion criteria: * corneal endothelial dystrophy
effects of weight loss on vascular function in obese subjects

Conditions: Obesity

Summary: to evaluate the effect of weight loss on vascular function in obese with poor cardiovascular health. the investigators will evaluate the effects of weight loss on total and central body adiposity, blood pressure, central hemodynamic parameters, arterial stiffness, endothelial function, apnea-hypopnea index, insulin resistance and inflammatory markers.

excessive adipose tissue is associated with adverse metabolic effects and is an important risk factor for chronic diseases. according to the american heart association, most cardiovascular events can be prevented by adhering to healthy practices, reflecting cardiovascular health as poor, intermediate, and ideal. methods: both sexes, aged between 40 and 70 years, with body mass index ≥ 30 and \< 40 kg/m² will be included and clinical, anthropometric, body composition and laboratory tests will be assessed. in vascular tests, the investigators will evaluate the sympathetic tone using a frequency meter (polar® rs800), oscillometric pulse wave analysis by mobil-o-grah®, post-occlusive microvascular reactivity and carotid ultrasound to measure intimamedia thickness. in the sleep study, the investigators will analyze the presence and degree of obstructive sleep apnea (osa) through the home polysomnography device (watchpat 200®). the first visit will be for screening, clinical and anthropometric evaluation. on the second visit, the vascular tests, instructions and device delivery for sleep study will be performed. patients will return the following day to return the watchpat and to receive the hypocaloric nutritional intervention (800kcal reduction of daily total energy value), which should be followed for 16 weeks. eight weeks after the beginning of the nutritional intervention a new visit will be scheduled for clinical, nutritional assessment and dietary adjustment. after completing 16 weeks, the patients will return for clinical, laboratory, nutritional, vascular and sleep tests.

Eligibility criteria:
inclusion criteria: * patients of both sexes; * age between 40 and 70 years; * body mass index (bmi) ≥ 30 kg/m² and \<40 kg/m². exclusion criteria: * systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmhg; * diabetes mellitus; hormone replacement therapy; * evidence of secondary hypertension; * clinically evident changes in thyroid function; * acute or chronic kidney or liver disease; * history of cancer in the last 5 years; * clinically evident coronary disease with a history of acute myocardial infarction and/or myocardial revascularization, clinical signs of heart failure, cardiac arrhythmia or clinically significant valve disease; * previous stroke;

Keywords: obesity weight loss cardiovascular diseases sleep apnea syndromes arterial stiffness endothelial dysfunction
rhythmic-based training with immersive mirror visual feedback for neuro-rehabilitation

Conditions: Stroke; Rehabilitation; Virtual Reality; Mirror Movement Therapy

Summary: in the proposed study, the investigators assumed that rhythmic-based training with immersive mirror visual feedback will provide a better treatment effects than traditional mirror therapy for the patients with unilateral stroke. the aim of the study is to examine the difference in the treatment effects among the combination of task-oriented training with either rhythmic-based training with immersive mirror visual feedback, or mirror therapy on the upper extremity function and brain activity of the stroke patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke with unilateral side involved; * a score of mini-mental state examination greater than 24 for proving higher mental function * time of onset \> 6 months before treatment begins; and * premorbid right-handedness. exclusion criteria: * severe vision and hearing impairment; * major cognitive-perceptual deficit; * other brain disease.
acute and longlasting side effects caused by radiotherapy in the head and neck area

Conditions: Head and Neck Cancer

Summary: the purpose of this clinical investigation is to evaluate acute and longlasting side effects in patients undergoing radiotherapy for cancer treatment in the head and neck area.

the "dental team" at the department for oral and maxillofacial surgery in trondheim takes care of patients before, during and also after radiotherapy in the head and neck area. in spite of the use of advanced radiation protocols and prevention measures such as fluoridation splints the team observes significant side effects, both under radiation and also on the long term after concluding treatment. common problems are for example dermal and mucosal damages, reduced salivation, dysphagia and lesions of the teeth. aim of the study is the investigation and documentation of side effects and complications in relation to the oral cavity. during the acute and postradiation phase a continuous follow-up over a longer lasting period is proceeded with registration of all relevant parameters. this includes among others dental status and evaluation of quality of life.

Eligibility criteria:
inclusion criteria: * radiation concerning the oral cavity * follow-up at the dental team exclusion criteria: * refused approval * survival prognosis under one year

Keywords: mouth mucositis dysphagia malnutrition xerostomia saliva tooth injuries